How lung fibrosis affects cancer immunity and treatment effectiveness
Lung fibrosis impairs tumor immunity and limits immune checkpoint efficacy
['FUNDING_CAREER'] · WASHINGTON UNIVERSITY · NIH-11113930
This study is looking at how lung fibrosis affects the immune system's ability to fight lung cancer, with the hope of finding better treatments for patients like you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11113930 on ClinicalTrials.gov |
What this research studies
This research investigates the relationship between lung fibrosis and the immune system's ability to fight lung cancer. The principal investigator, with a strong background in biochemistry and oncology, aims to understand how lung fibrosis impairs tumor immunity and limits the effectiveness of immune checkpoint therapies. By utilizing advanced techniques in molecular profiling and computational biology, the research will explore new ways to enhance anti-cancer immunotherapy. Patients may benefit from insights that could lead to improved treatment strategies for lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer who also have lung fibrosis.
Not a fit: Patients without lung cancer or those whose lung conditions do not involve fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for lung cancer patients with lung fibrosis.
How similar studies have performed: Previous research has shown promising results in understanding the tumor microenvironment's role in cancer immunity, suggesting that this approach could yield valuable insights.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HERZOG, BRETT HOWARD — WASHINGTON UNIVERSITY
- Study coordinator: HERZOG, BRETT HOWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy